Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1175-1179

  Cheah, C Y ^a   Chihara, D ^a   Romaguera, J E ^a   Fowler, N H ^a   Seymour, J F ^b,c   Hagemeister, F B ^a   Champlin, R E ^a   Wang, Michael L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bruton's tyrosine kinase inhibitors; Ibrutinib; Mantle cell lymphoma; Prognosis; Treatment

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IBRUTINIB; LACTATE DEHYDROGENASE; LENALIDOMIDE; METHOTREXATE; PLATINUM COMPLEX; RITUXIMAB; VINCRISTINE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG CANCER; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; VERY ELDERLY; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE COURSE; DRUG RESISTANCE; DRUG SUBSTITUTION; ENZYMOLOGY; KAPLAN MEIER METHOD; LYMPHOMA, MANTLE-CELL; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SALVAGE THERAPY; TEXAS; TIME FACTOR; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; DRUG SUBSTITUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; TEXAS; TIME FACTORS; TREATMENT FAILURE;

EID: 84933535494     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv111     Document Type: Article

References (14)

1. Geisler CH, Kolstad A, Laurell A et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112:2687-2693.
2. Hermine O, Hoster E, Walewski J et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). ASH Annual Meeting Abstracts 2010; 116:110.
3. Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23:7013-7023.
4. Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105:2677-2684.
5. Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520-531.
6. Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507-516.
7. Klapper W, Hoster E, Determann O et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009; 2:103-111.
8. Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059-3068.
9. Salaverria I, Zettl A, Bea S et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expressionbased proliferation signature. J Clin Oncol 2007; 25:1216-1222.
10. Martin P, Maddocks KJ, Noto K et al. Poor overall survival of patients with ibrutinibresistant mantle cell lymphoma. ASH Annual Meeting Abstracts. 2014.
11. Woyach JA, Furman RR, Liu T-M et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370:2286-2294.
12. Balasubramanian S, Schaffer M, Deraedt W et al. Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). ASH Annual Meeting Abstracts. 2014.
13. Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43:830-837.
14. Kopp N, Tschuri S, Haebe S et al. Newer-generation HSP90 inhibitors can overcome ibrutinib resistance and suppress proliferation in human mantle cell lymphoma in vitro and in vivo. ASH Annual Meeting Abstracts. 2014.